LITTLE FALLS, N.J.,
Oct. 7 /PRNewswire-FirstCall/ --
CANTEL MEDICAL CORP. (NYSE: CMN), through its Mar Cor
Purification subsidiary, has continued the expansion of its Water
Purification and Filtration segment by acquiring the exclusive
rights in the United States to
manufacture and sell Gambro's water treatment products used in the
production of water for hemodialysis. The total consideration for
the transaction with Gambro was $23.75
million and the licensed business had pre-acquisition
revenues of approximately $14
million. This transaction is expected to be slightly
accretive to Cantel's earnings per share in the first full year.
Curt Weitnauer, President of Mar
Cor Purification stated, "The Gambro heat-disinfection central
system is a great enhancement to our water-for-dialysis portfolio.
These new products will help us address two major trends in
dialysis water offerings: hot water disinfection and single
patient treatment. We'll be able to provide our dialysis clinic
customers the broadest and most advanced array of water treatment
alternatives from chemical to heat disinfection and single to
multi-patient systems."
Mar Cor will immediately commence sales and service of all
Gambro water products, components, parts and consumables solely
intended for the U.S. market. The manufacturing of these
products will be transitioned into Mar Cor's ISO 13485 Registered
Medical Device manufacturing facility in Plymouth, MN. Mar Cor will provide
service and support to Gambro's installed base of over 1,200
clinics and hospitals in the United
States. All U.S. employees aligned with Gambro's water
business will be offered employment with Mar Cor, which will help
provide a smooth transition for all Gambro customers.
Cantel's President and CEO, Andrew
Krakauer, added, "Building atop the success of our
acquisition of GE Water & Process Technologies' dialysis water
business and other Mar Cor regional acquisitions, we are continuing
to execute our strategy of marrying cutting-edge products with our
nationwide service network to fulfill the needs of our customers.
Our Water Purification and Filtration segment will now be
nearly $100 million in sales. I
am very pleased and confident in the leadership of our Mar Cor
group and anticipate both top and bottom-line synergies to result
from this unique opportunity."
About Mar Cor Purification, Inc.
With the addition of Denver,
Mar Cor Purification now has service offices in 20 cities in the
U.S. and Canada, with 7 resin
regeneration plants strategically located in Atlanta, Boston, Chicago, Montreal, Philadelphia, San
Antonio and Toronto. For
more information please visit http://www.mcpur.com.
About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of
infection prevention and control products in the healthcare market.
Our products include specialized medical device reprocessing
systems for renal dialysis and endoscopy, dialysate concentrates
and other dialysis supplies, disposable infection control products
primarily for the dental industry, water purification equipment,
sterilants, disinfectants and cleaners, hollow fiber membrane
filtration and separation products for medical and non-medical
applications, and specialty packaging for infectious and biological
specimens. We also provide technical maintenance for our products
and offer compliance training services for the transport of
infectious and biological specimens. For more information
please visit http://www.cantelmedical.com.
About Gambro
Gambro is a global medical technology company and a leader in
developing, manufacturing and supplying products and therapies for
Kidney and Liver dialysis, Myeloma Kidney Therapy, and other
extracorporeal therapies for Chronic and Acute patients. Gambro was
founded in 1964 and has today 8,000 employees, production
facilities in 9 countries, and sales in more than 100 countries.
For decades, Gambro has been first to market with many
groundbreaking innovations. By designing and delivering solutions
to dialysis clinics and intensive care units, Gambro offers not
just improved treatment quality, but also improved efficiency. For
more information please visit http://www.gambro.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
Contact:
|
Andrew A. Krakauer
|
Richard E. Moyer
|
|
|
President and CEO
|
Cameron Associates,
Inc.
|
|
|
Cantel Medical Corp.
|
richard@cameronassoc.com
|
|
|
Phone: (973) 890-7220
|
Phone: (212) 554-5466
|
|
|
|
|
SOURCE Cantel Medical Corp.
Copyright t. 7 PR Newswire